← Leaderboards
Anshu Agrawal
University Of California-Irvine
$3,499,313
Attributed
$4,823,890
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $738.1K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,823,890 · 5
By mechanism
R01$2,996,781 · 2
R33$1,102,954 · 1
R56$384,800 · 1
R21$339,355 · 1
Top collaborators
- Abraham P Lee4 shared
- Xiaolin Zi4 shared
- Michael B Lilly1 shared
Most similar at University Of California-Irvine
Same institution · by research overlap
- Roberto Tinoco$4,569,885
- Abraham P Lee$2,915,919
- Xiaolin Zi$5,893,861
- Anand K Ganesan$12,565,599
- Mei Kong$7,199,338
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteCellsAffectResponseT Cell ResponseIntegrinsDendritic CellsPlayProductionMalignant NeoplasmsImmune SystemAntigen-Presenting CellsImmune ResponseAntigensImmuneNeoplastic CellCytotoxic Cd8 T CellsRegulatory T-LymphocyteReportingInfluenzaCancer PatientCd8-Positive T-LymphocytesComplexAutologous
Grant awards (16)
Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer$359,138
R01 · FY2025 · CA
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy$156,730
R33 · FY2025 · CA
Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer$341,181
R01 · FY2024 · CA
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy$205,000
R33 · FY2024 · CA
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy$373,718
R33 · FY2023 · CA
Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer$351,711
R01 · FY2023 · CA
Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer$370,628
R01 · FY2022 · CA
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy$367,506
R33 · FY2022 · CA
Peripheral Immune mechanisms involved in the etiology of Alzheimer's disease$384,800
R56 · FY2019 · AG · contact PI
Impaired ability of aged human dendritic cells to maintain mucosal tolerance$316,725
R01 · FY2018 · AG · contact PI
Impaired ability of aged human dendritic cells to maintain mucosal tolerance$316,725
R01 · FY2017 · AG · contact PI
Impaired ability of aged human dendritic cells to maintain mucosal tolerance$316,725
R01 · FY2016 · AG · contact PI
Impaired ability of aged human dendritic cells to maintain mucosal tolerance$307,223
R01 · FY2015 · AG · contact PI
Impaired ability of aged human dendritic cells to maintain mucosal tolerance$316,725
R01 · FY2014 · AG · contact PI
Dendritic cell mediated modulation of tolerance by apoptotic cells in aging$151,780
R21 · FY2007 · AG · contact PI
Dendritic cell mediated modulation of tolerance by apoptotic cells in aged humans$187,575
R21 · FY2006 · AG · contact PI